Kaye Scholer represented Novartis subsidiary Sandoz, a world leader in generic pharmaceuticals, in a collaboration agreement with biotechnology company MedinCell. Under terms of the agreement, which was announced February 4, the alliance will develop and commercialize long-acting injectable drug products based on BEPO™ technology, with a primary focus on oncology.
The technology to deliver long-acting injectable drugs is rapidly advancing the world of pharmacology. The ability to provide a subcutaneous controlled release of drugs for days, weeks or even months has the potential to offer significant advantages over current delivery mechanisms, including patient compliance with a prescription regimen, efficacy and tolerability.
Corporate partner Aaron Gardner represented Sandoz in this transaction.
Also of Interest
- SEC Adopts New Rules: Fund Liquidity, Reporting and Disclosure, and “Swing Pricing” December 6, 2016 • Client Alerts
- NLJ Names Yates a 2016 Litigation Trailblazer December 6, 2016 • Recognitions
- Tax Alert: Final Debt Regulations Have Limited Scope of Application November 30, 2016 • Client Alerts
- Best Lawyers Profiles Frankle as “Lawyer of the Year” November 28, 2016 • Media Mentions
- Fallon Appointed to the University at Albany Presidential Search Committee November 22, 2016 • Recognitions
- Fintech Term Sheet Negotiations: Key Issues Beyond Price November 21, 2016 • Articles
- JUVE Handbuch Recommends Frankfurt Office and Lawyers November 14, 2016 • Recognitions
- Using Technology Service Providers Is No Silver Bullet November 7, 2016 • Articles
- Kaye Scholer Advises Bregal, Motion Equity in Morrison Utility Services Sale November 7, 2016 • Client Successes